TELA Bio launches SiteGuard No Rinse Antimicrobial Solution for plastic reconstructive surgery

TELA Bio, Inc.

SiteGuard uses Next Science's XBIO Technology to deconstruct biofilm and provide over 5 hours of protection.
TELA Bio entered exclusive distribution agreement in November 2021 to market the wash in US plastic reconstructive surgery.
First adjunctive soft-tissue technology complementing TELA's soft-tissue preservation and restoration product portfolio.
CEO Antony Koblish cites encouraging early test market experience and plans for nationwide expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.